Skip to content
← Catalog

Cancers 2025 · Review: CAR therapies ex vivo and in vivo · biomimetic nanoparticles

"Chimeric antigen receptor (CAR) therapy represents a promising modality for treating cancer and autoimmune diseases, employing genetically engineered immune cells. Despite remarkable clinical outcomes, its broad implementation is constrained by significant challenges, including…

Type
paper
Domain
oncology
Grade
conference
License
LIGHT_HOPE_proprietary
Provenance
m622_intel_seed_2026-05-16
evidence_grade
A
category
in_vivo_car_t_review
status
verified
instance_tag
sunvax-antibody-2025
clinical_claim_softening
"review article · industry framing · NOT primary clinical data"
journal
Cancers (Basel)
year
2025
authors
Ekaterina Tkachenko,Peter Timashev
abstract_snippet
"Chimeric antigen receptor (CAR) therapy represents a promising modality for treating cancer and autoimmune diseases, employing genetically engineered immune cells. Despite remarkable clinical outcomes, its broad implementation is constrained by significant challenges, includ
pmid
41374968
doi
10.3390/cancers17233766
View at source ↗

Read-only aggregated view. Conference Library is the source of record; this catalog shows provenance as-is — no ratings, no reviews.